Vnitr Lek 2024, 70(1):44-48 | DOI: 10.36290/vnl.2024.008

Expert opinion of representatives of professional societies on the position of finerenone in the treatment of type 2 diabetics with chronic kidney disease

Ondřej Viklický1, Vladimír Tesař2, Ivan Rychlík3, Martin Prázný4, Romana Ryšavá2, Richard Češka4, Martin Haluzík5, Petr Ošťádal6, Jan Krejčí7, Miloš Táborský8
1 Klinika nefrologie, Transplantační centrum, IKEM, Praha
2 Klinika nefrologie, VFN a 1. LF UK, Praha
3 Interní klinika FNKV a 3. LF UK, Praha
4 III. interní klinika VFN a 1. LF UK, Praha
5 Centrum diabetologie, IKEM, Praha
6 Kardiologická klinika 2. LF UK a FN Motol, Praha
7 I. interní kardioangiologická klinika, FN USA a LF MU, Brno
8 I. interní kardiologická klinika FN, LF UP, Olomouc

Both heart failure and chronic kidney disease (CKD) are detected more often in the type 2 diabetic population than in the general population. CKD screening should focus on its early detection to reverse, or at least significantly slow down its course and delay stage 5 CKD with the need for chronic dialysis or transplant treatment. Finerenone is a nonsteroidal, selective mineralocorticoid receptor antagonist. The effects of finerenone in patients with type 2 diabetes were investigated in the large registration phase III clinical trials FIDELIO-DKD, FIGARO-DKD and subsequently in their pooled analysis FIDELITY. Based on the results of published prospective randomized controlled trials with finerenone, its use in patients with CKD and type 2 diabetes is mentioned in several recent recommendations. Representatives of an expert panel including the Czech Nephrological Society, the Czech Diabetological Society, the Czech Internal Medicine Society and the Czech Cardiology Society, in accordance with recent international recommendations, consider finerenone to be one of the pillars of the treatment of patients with chronic kidney disease and type 2 diabetes for its nephroprotective and cardioprotective effects.

Keywords: finerenone, chronic kidney disease, heart failure, dialysis.

Accepted: February 9, 2024; Published: February 26, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Viklický O, Tesař V, Rychlík I, Prázný M, Ryšavá R, Češka R, et al.. Expert opinion of representatives of professional societies on the position of finerenone in the treatment of type 2 diabetics with chronic kidney disease. Vnitr Lek. 2024;70(1):44-48. doi: 10.36290/vnl.2024.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Pelikánová T, Viklický O, Rychlîk I, et al. Česká diabetologická společnost ČLS JEP, Česká nefrologická společnost a Česká společnost klinické biochemie ČLS JEP: Doporučené postupy při diabetickém onemocněnî ledvin 2017. Available from: https://www.cskb.cz/res/file/doporuceni/DM/dop_20170901_DKD.pdf
    2. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: Challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology. 2017;12(12):2032-2045. doi: 10.2215/CJN.11491116. Go to original source... Go to PubMed...
    3. Mora-Fernández C, Domínguez-Pimente V, de Fuentes MM, et al. Diabetic kidney disease: From physiology to therapeutics. Journal of Physiology. 2014;18(592):3997-4012. doi: 10.1113/jphysiol.2014.272328. Go to original source... Go to PubMed...
    4. Kenny HC, Abel ED. Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies. Circulation Research, vol. 124, no. 1. Lippincott Williams and Wilkins. 2019; Jan 04:121-141. doi: 10.1161/CIRCRESAHA.118.311371. Go to original source... Go to PubMed...
    5. Ceriello A, et al. Heart failure in type 2 diabetes: current perspectives on screening, diagnosis and management. Cardiovascular Diabetology. 2021; Dec. 011 (20). BioMed Central Ltd, . doi: 10.1186/s12933-021-01408-1. Go to original source... Go to PubMed...
    6. Marcovecchio ML, et al. Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia. 2009;6(52):1173-1181. , doi: 10.1007/s00125-009-1327-6. Go to original source... Go to PubMed...
    7. Mauer M, et al. Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. N Engl J Med. 2009;1(361):40-51. doi: 10.1056/NEJMoa0808400 Go to original source... Go to PubMed...
    8. Č. nefrologická Společnost: Dialyzační statistika. Available from: https://www.nefrol.cz/odbornici/dialyzacni-statistika
    9. Táborský M, et al. Trends in the treatment and survival of heart failure patients: a nationwide population-based study in the Czech Republic. ESC Heart Fail. Oct 2021;5(8):3800-08. doi: 10.1002/ehf2.13559. Go to original source... Go to PubMed...
    10. SPC přípravku Kerendia. Available from: https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_cs.pdf (cited 1.11. 2023)
    11. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-2229. doi: 10.1056/NEJMoa2025845 Go to original source... Go to PubMed...
    12. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-2263. doi: 10.1056/NEJMoa2110956 Go to original source... Go to PubMed...
    13. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022 Feb 10;43(6):474-484. doi: 10.1093/eurheartj/ehab777 Go to original source... Go to PubMed...
    14. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022 Nov;102(5S):S1-S127. doi: 10.1016/j.kint.2022.06.008. Go to original source... Go to PubMed...
    15. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-3639. Go to original source...
    16. American Diabetes Association Professional Practice Committee. 11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45(Supplement_1):S175-S184. https://doi.org/10.2337/dc22-S011 Go to original source... Go to PubMed...
    17. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002. Go to original source... Go to PubMed...
    18. de Boer IH, Khunti K, Sadusky T, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Dec 1;45(12):3075-3090. doi: 10.2337/dci22-0027. Go to original source... Go to PubMed...
    19. Pasternak M, et al. Association of Albuminuria and Regression of Chronic Kidney Disease in Adults With Newly Diagnosed Moderate to Severe Chronic Kidney Disease. JAMA Netw Open. Aug. 2022;8(5):e2225821. , doi: 10.1001/jamanetworkopen.2022.25821. Go to original source... Go to PubMed...
    20. Lezaic V. Albuminuria as a Biomarker of the Renal Disease, in Biomarkers in Kidney Disease, Springer Netherlands, 2015, pp. 1-18. doi: 10.1007/978-94-007-7743-9_31-1. Go to original source...
    21. www.sukl.cz (cited 1.11. 2023)

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.